Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05223933
Other study ID # 2017-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 12, 2016
Est. completion date December 29, 2018

Study information

Verified date January 2022
Source Institut Pasteur de Madagascar
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial took place in a rural area hyper endemic for malaria, the hypothesis of which was that active detection and treatment of malaria in the population (all ages combined) in the event of a positive test could reduce the prevalence of malaria in the region. zoned. It was a two-armed, randomized, cluster-based community intervention trial: - one arm with home treatment of malaria for the duration of the study for patients with a positive result in the rapid diagnostic test for malaria. - a control arm with the usual malaria management procedures (ie consultation with community workers or the nearest health centers in the event of fever or suspected signs of malaria). Before the start of monitoring, an initial survey (Baseline) was carried out in the "fokontany" (villages / cluster) included in the 2 arms, in order to determine the prevalence of malaria. Then, in the intervention arm, screening for malaria by RDT every 2 weeks in subjects with a suspected malaria case (fever or notion of fever in the 2 days preceding the visit) and treatment with Artesunate-amodiaquine (ACT) for patients with a positive RDT. At the end of the follow-up period, a final survey (Endline), based on the same questionnaires as during the Baseline, was carried out in the 2 villages of the 2 arms. As a secondary objective, a study on anemia in women aged between 15 and 49 years was also carried out during the baseline and endline periods in order to compare the prevalence between the 2 periods


Description:

This study aims to compare the prevalence of malaria in the rural community of Mananjary after the Malaria Home Care Program (PECADOM Plus). The study will take place in fokontany rural communes of the district of Mananjary. This district was chosen for the following reasons: - High prevalence of malaria in this area (31% in subjects with fever and attending medical consultation in the CSB included in the sentinel IPM fever site) - presence of Peace Corps Volunteers (PCV) in this district. Mananjary District is situated in southeastern Madagascar, located in the central part of the Vatovavy Fitovinany Region, in the province of Fianarantsoa. It is located at 21°13'52" South and 48°20'31" East. The district is composed of one urban commune and 28 rural communes. After obtaining the agreement of the ethics committee for the realization of the study, the coordinator or the assistant coordinator of the project will make courtesy visits to all administrative and health officials in the Vatovavy Fitovinany and Mananjary District (Regional Directorate, District Chief ...).A random draw of fokontany meeting the inclusion criteria will be carried out later, to identify the distribution of fokontany in the intervention arm and control arm in the project. In addition to the 22 fokontany required, a draw of 8 reserve fokontany will be made (4 for each arm). A courtesy visit will be conducted in the fokontany raffled. The coordinator will check the number of inhabitants in these fokontany with the information gathered at the time of the preparation of the protocol (projection of the population according to the data of INSTAT, information from the Medical Inspector of Mananjary). If the fokontany will not be eligible, the reserve fokontany will replace them in the study.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date December 29, 2018
Est. primary completion date December 12, 2016
Accepts healthy volunteers No
Gender All
Age group 2 Months and older
Eligibility Inclusion Criteria: - Inclusion criteria in community: - Fokontany in rural communes of Mananjary district (fokontany level of safety, accessibility by the study teams, and phone network availability was assessed). - Agreement of the chief of Fokontany for the participation of his fokontany in the study - Fokontany with at least 1,000 inhabitants - Individual inclusion criteria: - Resident in the relevant areas during the study period and consenting to participate Exclusion Criteria: - Exclusion criteria in community: - Fokontany with a total population of less than 1000 inhabitants - Fokontany in an urban commune - Fokontany in an area whose access is risky and perilous - Individual exclusion criteria: None (Non-resident present at the time of passage were tested in the study if they have suggestive signs of malaria but they were considered as visitors)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Proactive community case management
CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature = 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.

Locations

Country Name City State
Madagascar Fokontany Ambakoana Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Ambalamanasa Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Ambalaromba Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Ambinany Namorona Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Amboditandroho Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Ambohimiarina II Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Ambohinihaonana Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Ambolotara Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Andranomavo Mananjary : Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Andranomiteka Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Anilavinany Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Ankazotokana Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Anosimparihy Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Kianjavato Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Mahavoky Sud Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Manotro Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Maroamboka Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Sahafotahina Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Sandravakoka Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Tanambao Sud Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Tanambaobe Mananjary Fianarantsoa, Vatovavy Fitovinany
Madagascar Fokontany Tsarahafatra Mananjary Fianarantsoa, Vatovavy Fitovinany

Sponsors (4)

Lead Sponsor Collaborator
Institut Pasteur de Madagascar National Malaria Control Programme, Madagascar, Peace Corps, United States Agency for International Development (USAID)

Country where clinical trial is conducted

Madagascar, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint of the study was the change in the prevalence of malaria RDT positivity in the intervention versus control fokontany. Difference in differences (DiD) approach comparing baseline to endline is used to compare the prevalence of malaria RDT positivity in the 2 arms an average of 1 year
Secondary percent of households visited every two weeks percent of households visited every two weeks out of the number of the households registered in initial census The event was assessed up to 30 weeks (15 biweekly visits).
Secondary percent of households gave consent percent of households that were visited every two weeks and gave consent for the screening during each visit The event was assessed up to 30 weeks (15 biweekly visits).
Secondary Fever incidence percent of fever cases out of all individuals screened during each visit The event was assessed up to 30 weeks (15 biweekly visits).
Secondary Malaria incidence percent of persons with positive RDT and fever cases out of all individuals screened during each visit The event was assessed up to 30 weeks (15 biweekly visits).
Secondary fever cases with RDT performed percent of fever cases with RDT performed The event was assessed up to 30 weeks (15 biweekly visits).
Secondary RDT-positive persons treated with an ACT percent of RDT-positive persons treated with an ACT during each visit The event was assessed up to 30 weeks (15 biweekly visits).
Secondary The change in the prevalence of anemia in women aged between 15 and 49 years old in the intervention versus control fokontany Difference in differences (DiD) approach comparing baseline to endline is used to compare the prevalence of anemia in the 2 arms an average of 1 year
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02605720 - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns Phase 3